IP Library Granted Patent US 11,638,690
Granted Patent B2
US 11,638,690 · App. 17/112,458 · Granted May 2, 2023

Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device

Inventor: Mir Imran (Los Altos Hills, CA)
Assignee: Rani Therapeutics, LLC
A61K9/0053A61K9/4808A61K31/155A61K38/29A61M5/00A61M25/10A61M25/1011A61M31/00A61M37/0015A61K9/4858A61K9/4866A61M31/002A61M2025/105A61M2037/0023A61M2037/0061
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,638,690
App. No.
17/112,458
Granted
May 2, 2023
Kind
B2
Abstract

Embodiments of the invention provide swallowable devices, preparations and methods for delivering drugs and other therapeutic agents within the GI tract. Many embodiments provide a swallowable device for delivering the agents. Particular embodiments provide a swallowable device such as a capsule for delivering drugs into the intestinal wall or other GI lumen. Embodiments also provide various drug preparations that are configured to be contained within the capsule, advanced from the capsule into the intestinal wall and degrade to release the drug into the bloodstream to produce a therapeutic effect. The preparation can be operably coupled to delivery means having a first configuration where the preparation is contained in the capsule and a second configuration where the preparation is advanced out of the capsule into the intestinal wall. Embodiments of the invention are particularly useful for the delivery of drugs which are poorly absorbed, tolerated and/or degraded within the GI tract.

Claims (33)

1. An apparatus for delivering parathyroid hormone (PTH) or PTH analogue to a patient in need thereof, the apparatus comprising:

a swallowable enclosure having an interior;

an actuator within the interior of the swallowable enclosure; and

a PTH or PTH analogue preparation coupled to the actuator, the PTH or PTH analogue preparation supplied in the enclosure in a form which can be delivered from the enclosure into a gastrointestinal (GI) lumen wall by application of force on the preparation,

wherein the actuator has a first configuration and a second configuration, the preparation being contained within the interior in the first configuration and advanced out of the interior in the second configuration so as to deliver the PTH or PTH analogue preparation, and

wherein the actuator is configured to respond to a condition within the GI lumen by expanding from the first configuration into the second configuration, thereby delivering the PTH or PTH analogue preparation.

2. The apparatus of claim 1 , wherein the actuator is configured to respond to a condition with a small intestine of the patient by expanding from the first configuration into the second configuration.

3. The apparatus of claim 2 , wherein the condition within the GI lumen is a selected pH.

4. The apparatus of claim 1 , wherein a weight percent of PTH or PTH analogue in the PTH or PTH analogue preparation is about 1 to 2%.

5. The apparatus of claim 1 , wherein a dose of PTH or PTH analogue in the PTH or PTH analogue preparation is in a range from 10 to 30 μg.

6. The apparatus of claim 1 , wherein the preparation is a PTH analogue preparation comprising teriparatide.

7. The apparatus of claim 1 , wherein the PTH or PTH analogue preparation comprises at least one pharmaceutical excipient.

8. An apparatus for delivering parathyroid hormone (PTH) or PTH analogue to a patient in need thereof, the apparatus comprising:

a swallowable enclosure having an interior; and

a PTH or PTH analogue preparation coupled to the actuator,

wherein the enclosure is configured to protect the PTH or PTH analogue preparation from degradation by gastrointestinal fluids within a gastrointestinal (GI) lumen of the patient,

wherein the PTH or PTH analogue preparation is supplied in the enclosure in a form which can be delivered from the enclosure into a wall of the GI lumen by application of force on the preparation.

9. The apparatus of claim 8 , wherein the enclosure is configured to protect the PTH or PTH analogue preparation from degradation by gastrointestinal fluids within a stomach of the patient.

10. The apparatus of claim 8 , wherein a weight percent of PTH or PTH analogue in the PTH or PTH analogue preparation is about 1 to 2%.

11. The apparatus of claim 8 , wherein a dose of PTH or PTH analogue in the PTH or PTH analogue preparation is in a range from 10 to 30 μg.

12. The apparatus of claim 8 , wherein the preparation is a PTH analogue preparation comprising teriparatide.

13. The apparatus of claim 8 , wherein the PTH or PTH analogue preparation comprises at least one pharmaceutical excipient.

14. A method of delivering parathyroid hormone (PTH) or PTH analogue to a patient in need thereof, the method comprising:

swallowing a drug delivery device comprising a capsule, an actuator having a first configuration and a second configuration, and a PTH or PTH analogue preparation operably coupled to the actuator, the PTH or PTH analogue preparation being contained within the capsule in the first configuration of the actuator and advanced into a wall of a gastrointestinal (GI) lumen of the patient in the second configuration of the actuator, wherein the PTH or PTH analogue preparation is in a form deliverable from the enclosure into a wall of the GI lumen by application of force on the preparation by the actuator.

15. The method of claim 14 , wherein the actuator expands from the first configuration into the second configuration to advance the PTH or PTH analogue from the capsule and into the wall of the GI lumen in response to a condition in the GI lumen.

16. The method of claim 15 , wherein the condition within the GI lumen is a selected pH.

17. The method of claim 14 , wherein the GI lumen is a lumen of a small intestine of the patient.

18. The method of claim 14 , wherein, after being advanced into the wall of a GI lumen, the PTH or PTH analogue preparation is retained in the wall of the GI lumen.

19. The method of claim 18 , wherein a long-term release of the PTH or PTH analogue is produced by retaining the PTH or PTH analogue preparation in the wall of the GI lumen.

20. The method of claim 19 , wherein the long-term release has a duration of about 12 hours.

21. The method of claim 14 , wherein a dose of PTH or PTH analogue in the PTH or PTH analogue preparation is in a range from 10 to 30 μg.

22. The method of claim 14 , wherein the preparation is a PTH analogue preparation comprising teriparatide.

23. The method of claim 14 , wherein the PTH or PTH analogue preparation comprises at least one pharmaceutical excipient.

Assignments (3)
RELEASE OF SECURITY INTEREST Recorded Dec 19, 2025
From: AVENUE VENTURE OPPORTUNITIES FUND, L.P.
To: RANI THERAPEUTICS, LLC
Reel/Frame 073971/0117 →
SECURITY INTEREST Recorded Aug 9, 2022
From: RANI THERAPEUTICS, LLC
To: AVENUE VENTURE OPPORTUNITIES FUND, L.P., AS AGENT
Reel/Frame 061131/0478 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 4, 2020
From: IMRAN, MIR
To: RANI THERAPEUTICS, LLC
Reel/Frame 054601/0554 →
Continuity (10)
Continuation 16514967 · Jul 17, 2019
Continuation 15879308 · Jan 24, 2018
Continuation 15197094 · Jun 29, 2016
Continuation 13538875 · Jun 29, 2012
Continuation In Part 12978233 · Dec 23, 2010
Continuation In Part 12978164 · Dec 23, 2010
Continuation In Part 12978301 · Dec 23, 2010
Provisional Application 61571649 · Jun 30, 2011
Provisional Application 61571641 · Jun 29, 2011
Related Publication 20210085600A1 · Mar 25, 2021
Cited By (2)
US 12,263,325 US 12,268,831